Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 102

1.

A sensitive two-photon probe to selectively detect monoamine oxidase B activity in Parkinson's disease models.

Li L, Zhang CW, Chen GY, Zhu B, Chai C, Xu QH, Tan EK, Zhu Q, Lim KL, Yao SQ.

Nat Commun. 2014;5:3276. doi: 10.1038/ncomms4276.

PMID:
24522637
[PubMed - in process]
2.

The EcoRV genetic polymorphism of human monoamine oxidase type A is not associated with Parkinson's disease and does not modify the effect of smoking on Parkinson's disease.

Costa-Mallen P, Checkoway H, Fishel M, Cohen AW, Smith-Weller T, Franklin GM, Swanson PD, Costa LG.

Neurosci Lett. 2000 Jan 7;278(1-2):33-6.

PMID:
10643794
[PubMed - indexed for MEDLINE]
3.

Molecular mechanism of the relation of monoamine oxidase B and its inhibitors to Parkinson's disease: possible implications of glial cells.

Nagatsu T, Sawada M.

J Neural Transm Suppl. 2006;(71):53-65. Review.

PMID:
17447416
[PubMed - indexed for MEDLINE]
4.

Altered platelet monoamine oxidase-B activity in idiopathic Parkinson's disease.

Husain M, Shukla R, Dikshit M, Maheshwari PK, Nag D, Srimal RC, Seth PK, Khanna VK.

Neurochem Res. 2009 Aug;34(8):1427-32. doi: 10.1007/s11064-009-9929-4. Epub 2009 Mar 4.

PMID:
19259810
[PubMed - indexed for MEDLINE]
5.

Monoamine oxidase B inhibitors for early Parkinson's disease.

Macleod AD, Counsell CE, Ives N, Stowe R.

Cochrane Database Syst Rev. 2005 Jul 20;(3):CD004898. Review.

PMID:
16034956
[PubMed - indexed for MEDLINE]
6.

Parkin suppresses the expression of monoamine oxidases.

Jiang H, Jiang Q, Liu W, Feng J.

J Biol Chem. 2006 Mar 31;281(13):8591-9. Epub 2006 Feb 2.

PMID:
16455660
[PubMed - indexed for MEDLINE]
Free Article
7.

Comparative platelet proteome analysis reveals an increase of monoamine oxidase-B protein expression in Alzheimer's disease but not in non-demented Parkinson's disease patients.

Zellner M, Baureder M, Rappold E, Bugert P, Kotzailias N, Babeluk R, Baumgartner R, Attems J, Gerner C, Jellinger K, Roth E, Oehler R, Umlauf E.

J Proteomics. 2012 Apr 3;75(7):2080-92. doi: 10.1016/j.jprot.2012.01.014. Epub 2012 Jan 17.

PMID:
22270014
[PubMed - indexed for MEDLINE]
8.

MAO-B elevation in mouse brain astrocytes results in Parkinson's pathology.

Mallajosyula JK, Kaur D, Chinta SJ, Rajagopalan S, Rane A, Nicholls DG, Di Monte DA, Macarthur H, Andersen JK.

PLoS One. 2008 Feb 20;3(2):e1616. doi: 10.1371/journal.pone.0001616. Erratum in: PLoS One. 2012;7(8): doi/10.1371/annotation/3c37bef4-bb5e-4f1e-8551-01afc006df90.

PMID:
18286173
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Monoamine oxidase B (MAO B) inhibitor therapy in Parkinson's disease: the degree and reversibility of human brain MAO B inhibition by Ro 19 6327.

Fowler JS, Volkow ND, Logan J, Schlyer DJ, MacGregor RR, Wang GJ, Wolf AP, Pappas N, Alexoff D, Shea C, et al.

Neurology. 1993 Oct;43(10):1984-92.

PMID:
8413955
[PubMed - indexed for MEDLINE]
10.

Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.

Chen JJ, Swope DM, Dashtipour K.

Clin Ther. 2007 Sep;29(9):1825-49. Review.

PMID:
18035186
[PubMed - indexed for MEDLINE]
11.

M30, a novel multifunctional neuroprotective drug with potent iron chelating and brain selective monoamine oxidase-ab inhibitory activity for Parkinson's disease.

Gal S, Fridkin M, Amit T, Zheng H, Youdim MB.

J Neural Transm Suppl. 2006;(70):447-56.

PMID:
17017567
[PubMed - indexed for MEDLINE]
12.

Monoamine oxidase B inhibitors for the treatment of Parkinson's disease: a review of symptomatic and potential disease-modifying effects.

Schapira AH.

CNS Drugs. 2011 Dec 1;25(12):1061-71. doi: 10.2165/11596310-000000000-00000. Review.

PMID:
22133327
[PubMed - indexed for MEDLINE]
13.

Genetic polymorphism of monoamine oxidase B and susceptibility of Parkinson's disease.

Hwang WJ, Lai ML, Tsai TT, Lai MD.

Zhonghua Yi Xue Za Zhi (Taipei). 1997 Sep;60(3):137-41.

PMID:
9419949
[PubMed - indexed for MEDLINE]
14.

Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity.

Marzo A, Dal Bo L, Monti NC, Crivelli F, Ismaili S, Caccia C, Cattaneo C, Fariello RG.

Pharmacol Res. 2004 Jul;50(1):77-85.

PMID:
15082032
[PubMed - indexed for MEDLINE]
15.

Association of Catechol-O-Methyltransferase and monoamine oxidase B gene polymorphisms with motor complications in parkinson's disease in a Chinese population.

Hao H, Shao M, An J, Chen C, Feng X, Xie S, Gu Z, Chan P; Chinese Parkinson Study Group.

Parkinsonism Relat Disord. 2014 Oct;20(10):1041-5. doi: 10.1016/j.parkreldis.2014.06.021. Epub 2014 Jul 4.

PMID:
25034874
[PubMed - in process]
16.

Peripheral blood cell activities of monoamine oxidase B and superoxide dismutase in Parkinson's disease.

Checkoway H, Costa LG, Woods JS, Castoldi AF, Lund BO, Swanson PD.

J Neural Transm Park Dis Dement Sect. 1992;4:283-90.

PMID:
1388699
[PubMed - indexed for MEDLINE]
17.

Association of a monoamine oxidase B allele with Parkinson's disease.

Kurth JH, Kurth MC, Poduslo SE, Schwankhaus JD.

Ann Neurol. 1993 Apr;33(4):368-72.

PMID:
8489207
[PubMed - indexed for MEDLINE]
18.
20.

Chronic monoamine oxidase-B inhibitor treatment blocks monoamine oxidase-A enzyme activity.

Bartl J, Müller T, Grünblatt E, Gerlach M, Riederer P.

J Neural Transm. 2014 Apr;121(4):379-83. doi: 10.1007/s00702-013-1120-z. Epub 2013 Nov 23.

PMID:
24272680
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk